Articles tagged with Immunity
Researchers at Beth Israel Deaconess Medical Center found that newer Omicron subvariants BA.4 and BA.5 escape neutralizing antibodies induced by both vaccination and previous infection. These variants are now responsible for over 21% of new cases in the US, highlighting a shift in the COVID-19 landscape.
A UC San Diego study suggests COVID-19 rebound symptoms after taking Paxlovid are likely caused by insufficient drug exposure, not resistance or impaired immunity. The study found the virus remained sensitive to the drug and no relevant mutations were detected.
Scientists have discovered a new, high-resolution view of the rabies virus glycoprotein, which could lead to more effective vaccines. The study's findings suggest that a better-shaped vaccine could provide lifelong protection against the deadly disease.
Researchers have identified two broadly neutralizing antibodies that can effectively neutralize all SARS-CoV-2 variants, including Omicron BA.1 and BA.2 subtypes. The antibodies, Cv2.1169 and Cv2.3194, were found to be fully active against Alpha, Beta, Gamma, and Delta variants.
A recent study published in the New England Journal of Medicine found that COVID-19 vaccine immunity against new infection appears to wane rapidly, whereas people with a prior-infection were moderately protected from Omicron. Natural immunity provided strong and durable protection against severe illness.
Scientists have proven that inhaled aerosol vaccines provide stronger immune responses and better protection from respiratory infections compared to nasal sprays. This method delivers vaccine droplets directly into the airway, inducing a broader protective response.
A new preclinical study by Weill Cornell Medicine researchers shows that naturally-produced IgG antibodies in breast milk can protect infants from infection-induced diarrheal illness. These antibodies enhance infant immunity against bacterial pathogens causing gastrointestinal diseases.
Researchers discovered that pregnant women produce super antibodies to protect their newborns by altering the structure of sugars attached to the antibodies. This molecular change allows immunoglobulin G to stimulate immunity through receptors that respond specifically to deacetylated sugars, providing expanded protective role.
A study found that unvaccinated children develop a rapid immune response to SARS-CoV-2, which may contribute to less severe symptoms, but limits the development of an immune memory response. Vaccination is believed to strengthen immunity by inducing key components such as memory T cell and B cell responses.
Researchers at Nagoya University developed a chemical-only process to create customized mRNA vaccines, offering an inexpensive and large-scale production of mRNA. The new method allows for precise molecular design and stable mRNA with improved translational activity.
A third dose of COVID-19 vaccine may be essential for kidney transplant patients in Japan to prevent severe disease and infection. Researchers found that only a third of patients developed sufficient antibodies after two doses, highlighting the need for additional protection.
Researchers found that inhibiting caspase 11 reduced inflammation, tissue injury and blood clots in lung tissue of infected mice. This suggests potential therapeutic targets for treating severe COVID-19 symptoms.
A recent study published in The BMJ found that three doses of the same vaccine or a combination of different vaccines work equally well in preventing COVID-19 infections. The research suggests that the number of vaccine doses is key to improving immunity, rather than the combination of vaccine types.
Researchers at Washington State University have discovered that a specific population of CD4-positive helper T cells initiates antitumor immunity defenses, which can enhance the effectiveness of killer cell attacks on cancer cells. This finding holds promise for improving cancer immunotherapy response rates.
A new study found that the delta variant surge in the US was partially due to overestimating population immunity, with only 67% of southern New Englanders actually immune. This underestimation led to inaccurate projections and an incorrect assumption about herd immunity.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A new study analyzing 8 cohorts of COVID-19 patients found that antibody responses in previously infected individuals were relatively stable, providing protection from reinfection unless the new infection was the Omicron variant. Vaccination also boosted protection, with rapid immune responses observed even after a single vaccine dose.
Studies found people infected and vaccinated had similarly robust antibody responses against variants alpha through omicron; Immune memory cells against common cold coronaviruses may be markers of longer immunity. Researchers hope to improve vaccines with these insights.
A new study by Gladstone Institutes and UC San Francisco found that infection with the Omicron variant provides weak immune response in unvaccinated individuals, failing to confer broad protection against other variants. In contrast, vaccinated individuals show stronger immunity against multiple COVID-19 strains.
Researchers discovered that adaptive immune response against TB matures over time, with key players in immunity becoming activated by three months after infection. The emergence of these activated T cells is inversely correlated with the number of granuloma-contained live bacteria, suggesting they play critical roles in bacterial control.
Researchers found that a single mRNA vaccine booster shot can provide the same level of protection as three doses, making it a promising investment for resource-poor countries. The study suggests that this strategy could benefit billions of people worldwide and help combat emerging COVID-19 variants.
A new NIH-funded study will investigate the effects of semi-volatile organic compounds (SVOCs) on infant and childhood immunity, filling a knowledge gap in SVOC health impacts. The research aims to identify specific SVOCs or mixtures that impair immune function, which could lead to new preventive measures and interventions.
A study found that vaccines induce immune responses beyond neutralizing antibodies, involving T cells and the Fc receptor, to control viral replication and prevent severe disease. The researchers observed dose-dependent effects on these immune mechanisms, providing insights for future vaccine design and boosting.
Researchers found that individuals with a diverse population of macrophage cells, which include M2 and regulatory macrophages, are better protected against severe COVID-19. The study suggests that a balance between pro-inflammatory and anti-inflammatory responses is key to preventing the worst symptoms.
A new study published in PLOS Global Public Health found that shielding vulnerable populations while allowing the virus to spread through the rest of the population would have failed. The research reveals that even with perfect shielding, healthcare capacity would have been overwhelmed, and tens of thousands more deaths would have occu...
A UCLA-led team found that an abnormally suppressed immune system, not a persistently hyperactive one, may be to blame for some cases of long COVID-19. The study suggests boosting immunity in those individuals could be a treatment option.
A study found that prior symptomatic COVID-19 infection provided a similar degree of protection against reinfection as mRNA vaccination, with natural immunity offering a longer window of protection.
A new study assesses the degree and duration of protection against COVID-19 associated with natural immunity in 120,000 unvaccinated individuals. Researchers found that those who previously tested positive for SARS-CoV-2 had lower rates of subsequent COVID-19 infections.
Researchers discovered that checkpoint inhibitors can activate regulatory T cells, which can counteract the immune response. Blocking PD-L1 enhanced effector Treg activity, reducing ability to control parasite infections. This finding highlights complexity of immune system's balance between controlling pathogens and protecting healthy ...
Researchers have made a breakthrough in enhancing the antiviral T cell response triggered by therapeutic vaccines for chronic hepatitis B. By removing natural killer cells and activating them with cytokines, they boosted the control of HBV infection.
A recent study found that COVID-19 spreads extensively in households, with approximately 50% of household members infected from the first-infected individual. Children were less likely to spread the virus but equally likely to become infected as adults, highlighting their potential role in transmission.
Researchers at La Jolla Institute for Immunology discovered a Zika virus mutation that boosts its ability to replicate and infect humans. This mutation allows the virus to evade protective immunity from previous dengue exposure, increasing its transmission potential.
Researchers at Rutgers University propose a new approach to COVID-19 vaccine testing by combining conventional and challenge trials. This parallel approach, called Combining Conventional and Challenge trials (CCC), aims to facilitate faster and more accurate vaccine assessment and more effective pandemic response.
The newly developed COVID vaccine, PreS-RBD, targets the receptor binding domains of SARS-CoV-2 and induces a robust immune response. The vaccine has shown effectiveness in protecting against all known SARS-CoV-2 variants, including omicron, even in individuals who have not previously built up immunity.
Achieving classical herd immunity against SARS-CoV-2 may be unlikely due to virus mutations and asymptomatic transmission. However, widespread use of current public health interventions can control COVID-19 with minimal disruption.
The SAVE program, a NIH initiative, provides real-time risk assessment of SARS-CoV-2 variants on immune protection. It uses a coordinated approach to identify and curate data about these variants, their impact on immunity, and their effects on vaccine protection.
Researchers found that people who had COVID-19 and then got vaccinated generated an immune response more specific to fighting viral infections, producing a broader antibody response. This hybrid immunity also produced a cellular immune response called Th1 response, which is antiviral.
A booster dose of the Pfizer/BioNTech vaccine significantly increases antibodies against SARS-CoV-2, reversing a drop in immunity after two doses. In subjects given CoronaVac or Oxford-AstraZeneca vaccines, the booster raised immunity by a factor of 25 and 7, respectively.
A Mayo Clinic study of 106,349 primary care patients found that hospitalization rates for breakthrough COVID-19 were extremely low, even among those previously infected or vaccinated. The study supports previous findings that vaccination is the best way to prevent severe COVID-19 infection and hospitalization.
BGE-175 effectively prevents death in a mouse model of COVID-19 by reversing immune aging, suggesting its potential to protect elderly patients hospitalized with COVID-19. The drug restores the immune system to a more youthful state by blocking the PGD2-DP1 pathway.
A study found that double vaccinated individuals generate a potent and broad neutralizing antibody response after a delta breakthrough infection. This response provides protection against current variants of concern, including omicron.
A new study found that follicular T cells help balance out antibody diversity and affinity after COVID-19 vaccination. Deleting specific cell types altered the immune response, providing insights into strategies to enhance vaccine effectiveness later in life.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
Researchers discover unique glycoprotein structure of Nipah and Hendra viruses, which could provide blueprint for vaccine design and antibody treatments. The findings suggest a multi-pronged approach to prevent and treat these deadly illnesses.
Research reveals SARS-CoV-2 can have multiple variants in one person, with some hiding in specific cells like kidneys or spleens. This can make complete virus clearance more difficult, as the body struggles to defend against dominant strains.
Researchers found that two-dose mRNA vaccines against the original and early variants of the SARS-CoV-2 virus offer little to no protection against the omicron variant. A third COVID-19 mRNA vaccine booster shot, however, enhances immune response and provides comparable protection to the delta variant.
A new study from Oregon Health & Science University found that people infected with SARS-CoV-2 develop durable immunity against variants for at least 11 months. The research suggests that immune protection may endure long-term, potentially reducing the need for vaccine booster shots.
The WHO European Region has seen significant success in diphtheria immunization, with high coverage rates and only a few reported cases. However, suboptimal surveillance systems and inadequate laboratory capacity may contribute to the persistence of sporadic cases.
A recent review highlights the effects of different intestinal bacteria on colorectal cancer, exploring new therapies for disease prevention and treatment. Beneficial probiotics, such as Akkermansia muciniphila and Lactobacillus rhamnosus GG, exhibit anticancer properties and reduce CRC cell proliferation.
A study published in Immunogenetics found that male Kentish Plovers have stronger immune systems than females due to the presence of two active copies of immune genes on their Z chromosome. This may explain why males tend to survive longer than females in this species.
A new US-based study published in PLOS Biology found that most people who have had COVID-19 are protected against reinfection for at least six months. The research analyzed data from 4,441 SpaceX employees and estimated an odds ratio of 0.14 to 0.28 for reinfection depending on the time period considered.
A new study found that calorie restriction improves metabolic and immune responses, generating more T cells to fight off infections and improve energy efficiency. This could lead to a potential treatment to reduce age-related inflammation and improve metabolic health.
A Toronto study found that certain probiotic bacteria can alter the function of immune cells and spur cancer growth in pancreatic cancer. Deletion or inhibition of a key protein enabled better treatment sensitivity and more inflammatory T cells, while activation thwarted these effects.
A UC Davis Health study found that taking bile acids or treatments regulating their production levels can help control psoriasis inflammation. Bile acids inhibited skin inflammation by stopping immune T cells from producing proinflammatory protein IL-17A and blocking immune cell movement to the site.
Researchers found that macrophages feed on lactic acid produced by cancer cells, paralyzing killer immune cells and weakening tumour immunity. This discovery highlights the need to curb lactic acid production in tumours to improve immunotherapy outcomes.
A new study found that the Pfizer vaccine was 91% effective in reducing coronavirus transmission in Israeli households before the emergence of the delta variant. However, with waning immunity, the vaccine's effectiveness decreased to only 40% against infection and transmission.
A new study finds that breakthrough infections following vaccination and natural infection followed by vaccination provide roughly equal levels of enhanced immune protection. Researchers at OHSU found that both groups generated greater levels of immunity compared to those who were vaccinated with no infection.
Four COVID-19 vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize variants of concern, including Delta and Omicron. Fully vaccinated people have fewer memory B cells and neutralizing antibodies against the Omicron variant.
A recent study found that individuals vaccinated three times or those who were vaccinated after an earlier COVID-19 infection had comparable neutralizing antibody activity to those with a breakthrough case. The study suggests that repeated exposure to SARS-CoV-2 antigens enhances the quality of antibody responses.
A UK study found that over a third of care home residents and a quarter of staff in England showed evidence of SARS-CoV-2 infection during the first two waves of the pandemic. The study also revealed that antibodies against the virus became undetectable in half of the population within eight months.